What is the outlook for the Medibank dividend in FY23?

How good will the FY23 payout be from Australia's biggest private health insurer?

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Medibank paid a sizeable dividend in FY22 of 13.4 cents per share
  • There are projections Medibank could pay a bigger dividend in FY23 and FY24 of 15.2 cents per share and 15.8 cents per share, respectively
  • Medibank is predicting policyholder growth in FY23

The Medibank Private Limited (ASX: MPL) dividend might be attractive for some investors focused on investment income.

Medibank is the largest private health insurer in Australia, giving it good scale benefits. This enables it to make a good profit and pay attractive dividends.

Firstly, let's look at Medibank's dividend from FY22.

A male doctor and a woman in scrubs in the foreground smile.

Image source: Getty Images

FY22 dividend recap

In the FY22 result, Medibank's board decided to declare a final dividend of 7.3 cents per share. This was an increase of 5.8% year over year.

Overall, the business saw group net profit after tax (NPAT) fall 10.7% to $393.9 million due to net investment income falling from a $120 million gain in FY21 to a $24.8 million loss in FY22. However, the operating profit rose 12.5% to $594.1 million in FY22.

The full-year dividend was 13.4 cents per share, representing an increase of 5.5% compared to FY21.

Medibank's full-year dividend represented a payout ratio of 84.8% of underlying NPAT, normalising for investment market returns. This was at the top end of its target payout ratio range of between 75% to 85%.

At the current Medibank share price, this means it has an FY22 grossed-up dividend yield of 5.5%.

How big is the Medibank dividend expected to be in FY23?

Different analysts have different estimates for how much profit and how big the dividend may be from Medibank in the next couple of financial years.

For example, using the estimates on CMC Markets, Medibank is expected to generate earnings per share (EPS) of 18.4 cents in FY23 and 19.1 cents per share in FY24. This could translate into a dividend per share of 15.2 cents per share in FY23 and 15.8 cents per share in FY24. In percentage terms, this could mean a grossed-up dividend yield of 6.25% in FY23 and 6.5% in FY24.

Those dividend yields are pretty sizeable and would be attractive in my opinion. It could be a useful yield in this uncertain economic climate.

Let's have a look at a couple of the other estimates.

The broker Citi, which rates Medibank as a buy, thinks that Medibank could pay a grossed-up dividend yield of 6.5% in FY23 and 6.7% in FY24.

However, there are other estimates that put future dividends at a lower level. For example, Ord Minnett has projected that Medibank could pay a grossed-up dividend yield of 6.2% in FY23 followed by a grossed-up dividend yield of 6.6% in FY24.

Foolish takeaway

The private health insurer could generate a higher profit in FY23 with policyholder growth (projected by the company to be 2.7% in FY23). There could also be productivity improvements relating to management expenses and targeted organic or 'inorganic' growth. It's also possible that its investments could deliver gains again in FY23.

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman is very excited about something she's just seen on her computer, clenching her fists and smiling broadly.
Healthcare Shares

Telix shares are up 98%: Is there more upside to come?

The bull case remains compelling: rapid growth, rising profits and broker optimism.

Read more »

Concept image of a businessman riding a bull on an upwards arrow.
Healthcare Shares

How CSL shares skyrocketed 39% in August

Investors sent CSL shares rocketing 39% in August. But why?

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Sonic Healthcare shares crash 21%: What on earth is going on?

Do you hold the ASX healthcare shares in your portfolio?

Read more »

Couple looking ahead with laptop open at a table.
Healthcare Shares

Regis Healthcare reacts to government funding change

Regis Healthcare says government funding will rise just 2.55% as wage and cost inflation run much higher across the sector.

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares rebound 86%: Is the ASX biotech stock a buy, sell or hold for September?

Find out why investors are now rushing to buy CSL shares.

Read more »

A medical researcher wearing a white coat sits at her desk in a laboratory conducting a test.
Healthcare Shares

Could this 7%-yielding ASX healthcare share be a growth winner?

The current weakness could be catching the eye of passive income investors.

Read more »

Two scientists looking at a tablet.
Healthcare Shares

CSL shares are up more than 40% in a month. What just happened in the US?

The stock’s huge rebound is getting another boost.

Read more »

Woman flexes muscles after donating blood.
ASX Share Market News

Where will CSL shares be in 12 months? Brokers weigh in

Analysts remain divided over CSL’s recovery prospects.

Read more »